VIDEO: Study investigates novel therapy for penetration of pediatric brain tumors

ByCassie Kline, MD, MAS

ByGeorgia I Salvaryn

Fact checked byMindy Valcarcel, MS

PHILADELPHIA — In this video, Cassie Kline, MD, MAS, discusses the results of the PNOC016 trial she presented at International Symposium on Pediatric Neuro-Oncology.

The study observed the intratumoral pharmacokinetics and pharmacodynamic results of fimepinostat (Curis) in treating high-risk brain tumors in children and young adults with newly diagnosed diffuse intrinsic pontine gliomas, recurrent medulloblastoma or recurrent high-grade gliomas.

“[These] novel clinical trials [explore] not just the impact of drug on survival but [look] at intratumoral drug penetration and pharmacodynamic markers of response and [present] on ways in which we should be thinking about trial design and how we are answering or addressing questions of ‘how’ or ‘why’ a drug is working,” Kline, a pediatric neuro-oncology attending and director of neuro-oncology clinical research at Children’s Hospital of Philadelphia, said.

Reference:

Kline C, et al. Abstract TRLS-07. Presented at: International Symposium on Pediatric Neuro-Oncology; June 28-July 2, 2024; Philadelphia.

Published by:

Sources/Disclosures

Collapse

Disclosures: Kline reports grants from and/or clinical trial contracts with Bristol Myers Squibb, Cannonball Kids’ cancer Foundation, Chimerix, Curis, Day One Biopharmaceuticals, Ipsen, Kazia Therapeutics, Kortney Rose Foundation, Midatech Pharma and Regeneron Pharmaceuticals.

Take Homes from ISPNO

Read more

VIDEO: Study investigates novel therapy for penetration of pediatric brain tumors

Reference:

Related Content